Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
CRY-1, a regulator of our circadian clocks, contributes to disease spread and poor outcomes in prostate cancer patients by boosting DNA repair mechanisms that render cells more resistant to treatments, a ... Read more
Adding four months of androgen deprivation therapy (ADT) to radiation treatment extends survival and delays metastasis in men with unfavorable intermediate-risk prostate cancer, according to a secondary analysis of a Phase ... Read more
Treating prostate cancer animal models with modified immune cells that were isolated from bone marrow led to a significant reduction in tumor growth, a study in mice reports. These findings ... Read more
Researchers at Stony Brook University have been awarded a five-year, $4.2 million grant from the National Cancer Institute (NCI) to expand work into promising therapeutic agents against metastatic prostate cancer. ... Read more
More men with castration-resistant prostate cancer saw their prostate cancer antigen (PSA) levels — a marker of the disease — decline when they took Xtandi (enzalutamide) after Zytiga (abiraterone acetate) ... Read more